Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RX...

Industry: Biotechnology

Sector: Healthcare

Phone: 610 947 0251

Website: phiopharma.com

Address:

411 Swedeland Road, Suite 23-1080, King of Prussia, United States

HaroldH Aug. 24 at 12:10 PM

$PHIO fake bullish news running out. Interested to see how many cash in their chips before the going gets rough. I remain bearish.

0 · Reply

Ksa966 Aug. 21 at 4:12 PM

$PHIO my average 1.42 … is this go back

1 · Reply

MambaMentality7 Aug. 21 at 3:22 PM

$PHIO Just collect your winnings:)

0 · Reply

Avennite Aug. 20 at 5:14 PM

$PHIO Ronald Todd Plott, a director at Phio Pharmaceuticals Corp. (NASDAQ:PHIO), purchased 15,000 shares of the company’s common stock on August 19, 2026. The shares were acquired at a price of $1.14 each, totaling $17,100. Ok, it now looks like more than just the CEO are buying shares with their own money. https://www.investing.com/news/insider-trading-news/phio-pharmaceuticals-director-plott-buys-17100-in-shares-93CH-4869825

0 · Reply

PitaPierogi Aug. 20 at 12:00 PM

$PHIO Its latest 10-Q, covering through June 30, 2026, states that through the date the financial statements were issued: it “did not sell any shares” under the ATM and received no proceeds from it. So as of the August 6 filing: ATM authorized: $6.36M ATM shares sold: $0 ATM proceeds received: $0 Should clear that up for you.

0 · Reply

maurizio58 Aug. 20 at 8:21 AM

$PHIO My impression is that they are conducting an ATM offering and gifting shares to some friend, who—following the news expected in the third quarter—will put them back on the market at prices much higher than current levels.

0 · Reply

maurizio58 Aug. 20 at 8:19 AM

$PHIO If they were to make an offer, I assume they would have to issue a statement, so we are waiting for news. If, on the other hand, they were to use an ATM program, we wouldn't know until the end of the current quarter.

0 · Reply

maurizio58 Aug. 20 at 8:17 AM

$PHIO Capital raising – Q2 2026 In April 2026, the Company established an "at-the-market" (ATM) equity offering program under which it may offer and sell, from time to time, through HC Wainwright & Co., LLC acting as sales agent, common shares for an aggregate sales price of up to $6.36 million

0 · Reply

PitaPierogi Aug. 19 at 11:38 PM

$MRNA phio could be a buyout opportunity to stop the cure. They are tiny cap. $PHIO

0 · Reply

PitaPierogi Aug. 19 at 11:35 PM

$MRNA $MRK $PHIO Phio is trying to do something much bigger than just another skin-cancer drug. PH-762 uses self-delivering siRNA to silence PD-1 directly inside the tumor, essentially removing one of the brakes that prevents T-cells from attacking cancer. For PHIO's lead drug PH-762, the cancers they're currently targeting are primarily skin cancers: Cutaneous squamous cell carcinoma (cSCC) — this is the big one right now and where the strongest human results have been. Melanoma — including advanced/stage IV melanoma. Merkel cell carcinoma — a rare, aggressive skin cancer

0 · Reply

Phio Pharmaceuticals Proxy statement: Proxy filing

Aug 14, 2026, 8:00 AM EDT - 10 days ago

Phio Pharmaceuticals Proxy statement: Proxy filing

Aug 6, 2026, 4:05 PM EDT - 17 days ago

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Aug 6, 2026, 7:00 AM EDT - 18 days ago

Phio Pharmaceuticals Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 18 days ago

Phio Pharmaceuticals Earnings release: Q2 2026

Jul 22, 2026, 12:30 PM EDT - 4 weeks ago

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Jul 22, 2026, 7:00 AM EDT - 4 weeks ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Jul 21, 2026, 7:00 AM EDT - 4 weeks ago

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Jul 15, 2026, 7:00 AM EDT - 5 weeks ago

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

Jul 1, 2026, 8:00 AM EDT - 7 weeks ago

Phio Pharmaceuticals Slides: Corporate presentation

Jun 29, 2026, 12:00 PM EDT - 2 months ago

Phio Pharmaceuticals Transcript: Fireside chat

Jun 25, 2026, 3:00 PM EDT - 2 months ago

Phio Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum

Jun 24, 2026, 7:00 AM EDT - 2 months ago

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

May 7, 2026, 4:05 PM EDT - 3 months ago

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 7, 2026, 7:00 AM EDT - 3 months ago

Phio Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Phio Pharmaceuticals Earnings release: Q1 2026

Apr 15, 2026, 12:00 PM EDT - 4 months ago

Phio Pharmaceuticals Transcript: Fireside chat

Apr 14, 2026, 10:30 AM EDT - 4 months ago

Phio Pharmaceuticals Transcript: Second Annual Centri Capital Conference

Apr 13, 2026, 7:00 AM EDT - 4 months ago

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement

Mar 16, 2026, 11:30 AM EDT - 5 months ago

Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office

Mar 12, 2026, 11:00 AM EDT - 5 months ago

Phio Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum

Mar 10, 2026, 8:35 AM EDT - 5 months ago

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT

Mar 10, 2026, 7:00 AM EDT - 5 months ago

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

Mar 5, 2026, 4:05 PM EST - 6 months ago

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

Mar 5, 2026, 4:00 PM EST - 6 months ago

Phio Pharmaceuticals Annual report: Q4 2025

Mar 5, 2026, 4:00 PM EST - 6 months ago

Phio Pharmaceuticals Earnings release: Q4 2025

Mar 5, 2026, 4:00 PM EST - 6 months ago

Phio Pharmaceuticals Annual report: Q4 2025

Feb 24, 2026, 7:00 AM EST - 6 months ago

Phio Pharmaceuticals Slides: Corporate presentation

Feb 10, 2026, 7:00 AM EST - 6 months ago

Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Jan 26, 2026, 8:15 AM EST - 7 months ago

Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

Jan 20, 2026, 9:30 AM EST - 7 months ago

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

Jan 15, 2026, 8:45 AM EST - 7 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Dec 23, 2025, 8:45 AM EST - 8 months ago

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nov 25, 2025, 11:30 AM EST - 9 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

2025-11-20T21:11:11.000Z - 9 months ago

Phio Pharmaceuticals files to sell 11.76M shares of common stock for holders

Nov 20, 2025, 7:00 AM EST - 9 months ago

Phio Pharmaceuticals Registration statement: Registration Filing

Nov 17, 2025, 8:45 AM EST - 10 months ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 13, 2025, 4:15 PM EST - 10 months ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 13, 2025, 7:00 AM EST - 10 months ago

Phio Pharmaceuticals Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Phio Pharmaceuticals Quarterly report: Q3 2025

Nov 7, 2025, 10:30 AM EST - 10 months ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 7:45 AM EST - 10 months ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 3, 2025, 1:40 PM EST - 10 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

2025-11-03T14:24:44.000Z - 10 months ago

Why Is Phio Pharmaceuticals Stock Up 75% Today?

Nov 3, 2025, 7:45 AM EST - 10 months ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Oct 31, 2025, 10:15 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Sep 18, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 3, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Proxy statement: Proxy Filing

Aug 15, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Registration statement: Registration Filing

2025-08-15T10:10:23.000Z - 1 year ago

Phio Pharmaceuticals files to sell 1.93M shares of common stock for holders

Aug 14, 2025, 4:15 PM EDT - 1 year ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Earnings release: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Quarterly report: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Proxy statement: Proxy Filing

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Proxy statement: Proxy Filing

Jul 25, 2025, 3:04 PM EDT - 1 year ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 1 year ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

2025-06-05T10:15:09.000Z - 1 year ago

Phio Pharmaceuticals assumed with a Buy at H.C. Wainwright

May 19, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 1 year ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Earnings release: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Quarterly report: Q1 2025

May 7, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 1 year ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Earnings release: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Annual report: Q4 2024

Mar 10, 2025, 7:45 AM EDT - 1 year ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

2025-01-21T21:45:15.000Z - 1 year ago

Phio Pharmaceuticals files to sell 5.93M shares of common stock for holders

Jan 21, 2025, 4:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 21, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Registration statement: Registration Filing

Jan 16, 2025, 1:00 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2025-01-16T16:10:29.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

AZTR BDTX ERNA GTBP IBIO KAPA SLXN

2025-01-15T16:15:41.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

ARDX CGEN CLRB IBIO MRNA

Jan 15, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2025-01-14T14:40:47.000Z - 1 year ago

Phio Pharmaceuticals Corp trading resumes

2025-01-14T14:35:14.000Z - 1 year ago

Phio Pharmaceuticals Corp trading halted, volatility trading pause

Jan 14, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 14, 2024, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Quarterly report: Q3 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Phio Pharmaceuticals Earnings release: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

Phio Pharmaceuticals Quarterly report: Q2 2024

2024-07-26T20:33:23.000Z - 2 years ago

Phio Pharmaceuticals files to sell 1.13M shares of common stock for holders

Jul 26, 2024, 8:00 AM EDT - 2 years ago

Phio Pharmaceuticals Registration statement: Registration Filing

2024-07-08T14:05:37.000Z - 2 years ago

Phio Pharmaceuticals Corp trading resumes

2024-07-08T14:00:37.000Z - 2 years ago

Phio Pharmaceuticals Corp trading halted, volatility trading pause

2024-07-03T20:50:02.000Z - 2 years ago

Phio Pharmaceuticals Corp trading halted, news pending

2024-05-20T21:05:00.000Z - 2 years ago

Phio Pharmaceuticals files $100M mixed securities shelf

May 20, 2024, 8:00 AM EDT - 2 years ago

Phio Pharmaceuticals Registration statement: Registration Filing

2024-05-17T20:46:48.000Z - 2 years ago

Phio Pharmaceuticals files $100M mixed securities shelf

2024-05-17T13:02:30.000Z - 2 years ago

Phio Pharmaceuticals entered into purchase agreement with TRITON Funds

HaroldH Aug. 24 at 12:10 PM

$PHIO fake bullish news running out. Interested to see how many cash in their chips before the going gets rough. I remain bearish.

0 · Reply

Ksa966 Aug. 21 at 4:12 PM

$PHIO my average 1.42 … is this go back

1 · Reply

MambaMentality7 Aug. 21 at 3:22 PM

$PHIO Just collect your winnings:)

0 · Reply

Avennite Aug. 20 at 5:14 PM

0 · Reply

PitaPierogi Aug. 20 at 12:00 PM

0 · Reply

maurizio58 Aug. 20 at 8:21 AM

0 · Reply

maurizio58 Aug. 20 at 8:19 AM

0 · Reply

maurizio58 Aug. 20 at 8:17 AM

0 · Reply

PitaPierogi Aug. 19 at 11:38 PM

$MRNA phio could be a buyout opportunity to stop the cure. They are tiny cap. $PHIO

0 · Reply

PitaPierogi Aug. 19 at 11:35 PM

0 · Reply

PitaPierogi Aug. 19 at 11:32 PM

$MRNA $MRK $PHIO is also developing a shot to cure cancer. Its tiny. Potential buyout. Phio PH-762 = self-delivering RNAi designed to silence PD-1 locally inside the tumor.

0 · Reply

DosGatos Aug. 19 at 11:00 PM

$PHIO chump change tokem buy for CEO lol!

0 · Reply

CEOBuysDisclosures Aug. 19 at 10:05 PM

$PHIO CEO purchased 10,000 shares at $1.06 for a total of $10,600. Bitterman Robert J now owns 431,421 shares. https://ceo-buys.com

0 · Reply

MambaMentality7 Aug. 19 at 8:07 PM

$PHIO Nice after hours move. Will be interesting if the daily candle can hold.

0 · Reply

PitaPierogi Aug. 19 at 3:28 PM

$PHIO maybe we'll slowly rise on $MRNA and $MRK news. phio will be the direct competition. At a fraction of the price. Maybe they'll buy them out. $LLY $JNJ

0 · Reply

MambaMentality7 Aug. 19 at 3:13 PM

$PHIO this is a cash raise. The company needs to raise money because they are burning cash preparing for FDA APPROVAL which is good news. They wouldn’t spend money on this if they weren’t ready with good news. The downside is our shares have been diluted in the process. Not a lot but definitely some. They are selling directly to retail and that caused the spike today. Close but not today:) Set your alerts and go play with the kids.

1 · Reply

hardrock2112 Aug. 19 at 2:32 PM

$PHIO yes I am ...

0 · Reply

Ksa966 Aug. 19 at 2:04 PM

$PHIO is there any news?

0 · Reply

PitaPierogi Aug. 19 at 1:50 PM

$PHIO jane street is in boys. We fly soon

0 · Reply

PitaPierogi Aug. 19 at 1:19 PM

$PHIO 1000% gainer soon.

1 · Reply

Jazz20 Aug. 19 at 12:27 PM

$PHIO 💪

0 · Reply

HaroldH Aug. 19 at 10:45 AM

$PHIOBULLS seem unable to string a logical argument in favor of $PHIO. wonder why that is. Bulls weak?

1 · Reply

Market Cap	13.71M
Revenue (ttm)	0.00
Net Income (ttm)	-8.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	204,456
Avg Vol	733,710
Day's Range	N/A - N/A
Shares Out	11.62M
Stochastic %K	71%
Beta	0.82
Analysts	Sell
Price Target	$14.00